Upper limb function of patients with multiple sclerosis (MS) is increasingly acknowledged as important as upper limb disability has an impact on the performance of daily life activities and reduces quality of life. In order to investigate whether an intervention (drugs therapy and rehabilitation) has an impact on upper limb disability, outcome measures with good psychometric properties are required. In a topical review on upper limb assessment, 1 we concluded that no single outcome measure covers the entire range of upper limb functionality as defined by the International Classification of Functioning, Disability and Health (ICF) and is applicable with sensitivity across different upper limb disability levels. The Nine-Hole Peg Test (NHPT) is however one of the best proxies for measuring upper limb capacity in MS. 2 In recent years, patient-reported outcome measures (PROMs) are acknowledged as an important part of upper limb assessment in MS as they provide more information about the difficulties MS patients experience when performing activities of daily life (ADL) with their upper limb, the latter being considered as the ultimate goal of upper limb treatment. Different studies 3, 4 have indicated that scores on capacity measures (e.g. NHPT or Action Research Arm test) are not highly related to PROMs, indicating that they measure different concepts. It was even demonstrated that some MS patients with (almost) normal scores on capacity measures report upper limb disability affecting their ADL performance. Therefore, we recommend the inclusion of PROMs in clinical trials and practice and hypothesize that they may be even more sensitive to detect activity limitations in early MS stages than unilateral capacity tests.
To date, different PROMs developed for other neurological diseases or diseases causing upper limb disability are being used to assess the upper limbs disability in MS. These PROMs have a lot in common such as the activities included in the questionnaire (e.g. washing hands, using a knife, buttoning clothes, turning a key, opening a jar or bottle) but also some differences such as the specific questions asked and the scoring method. The most frequently used PROMs in intervention and cross-sectional studies so far are the ABILHAND 5 and Manual Ability Measure-36 (MAM-36). 6 Both PROMs measure the perceived ease or difficulty that a person may experience when performing ADL regardless of which upper limb they use. There are however some differences between these two PROMs which are conducted during a semi-structured interview. The ABILHAND consists of 23 exclusively bilateral ADL tasks that are scored using a three-point ordinal scale while the MAM-36 consists of 36 unilateral and bilateral ADL tasks which are scored using a 4-point ordinal scale (0-4). For both the ABILHAND and MAM-36, a conversion table is available to obtain a Rasch-derived score, which is regarded as superior to a summed score or calculated scores. The Disabilities of the Arm, Shoulder, and Hand Scale (DASH) 7 and the Motor Activity Log (MAL) 8 are less frequently used PROMs in MS and make use of summed or calculated total score. The DASH measures the symptoms of upper limb dysfunction and the ability to perform unilateral and bilateral activities by asking the patient to rate 30 tasks related to daily life using a 5-point ordinal scale reflecting the ease or difficulty perceived while performing the task. The MAL measures, during a semi-structured interview, how much (amount of use scored from 0 to 5) and how well (quality of movement scored from 0 to 5) a patient uses their moreaffected upper limb relative to its pre-illness use across 30 common, primarily unilateral ADL. While this is an attractive construct that relates to upper limb performance in daily life, it may be difficult for MS patients to compare their current upper limb functioning with a situation 'pre-illness'. bilateral daily life activities using a 6-point ordinal scale. The AMSQ-short form that is introduced in the current issue contains only 10 items and seems a promising assessment tool in research and clinical practice. 10 While applying a MS-specific scale seems appealing, and may be widely applied similar to the now acknowledged Multiple Sclerosis Walking Scale-12 (MSWS-12), it limits comparison with historical data in MS and other pathologies.
Psychometric properties of these PROMs were investigated using Rasch measurement methods or standard methods (intraclass correlations, standard error of measurement). The ABILHAND, 11 MAM-36 6 and the AMSQ 12 appeared to be reliable and valid in MS, in contrast to the low psychometric properties that were found for the DASH 13 and the lack of data for the MAL. Responsiveness in relation to the longitudinal progression of the MS (deterioration) or with improvement after treatment of MS patients has not yet been investigated for any of these PROMs which makes it premature to include any one as a primary outcome measure in clinical trials. Most of the PROMs are available in different languages but cross-cultural validity was rarely investigated. It is strongly advised to design studies that directly compare the sensitivity of the different PROMs across MS patients with different upper limb disability levels in different countries and in comparison with clinical capacity tests such as the NHPT. Besides, the comparative sensitivity of PROMs compared to capacity measures to detect progression in clinical trials in progressive MS is also required as it has recently been shown that the MSWS-12 is more sensitive than the capacity walking tests in the early MS stage (Expanded Disability Status Scale 1-3). 14 In conclusion, including PROMs to measure upper limb disability in MS is highly recommended and there are currently methodologically sound PROMs available which can be used in research and clinical practice. Further research is however needed to investigate the psychometric properties, in particular responsiveness, in the total MS population and subgroups of different upper limb disability levels.
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